Bristol-Myers offloads manufacturing plant to Catalent 13-Jan-2020 By Nick Taylor Catalent buys Italian manufacturing and packaging plant from Bristol-Myers Squibb, adding oral solid, biologics and sterile product capacity.
UPDATED Catalent continues expansion spree with BMS manufacturing facility 19-Jun-2019 By Ben Hargreaves Catalent to purchase BMS’s Italian manufacturing facility to gain access to fill/finish capabilities, following several large-scale deals this year.
EU rules Avastin can be reimbursed for off-label use 30-Nov-2018 By Maggie Lynch The European Court of Justice has determined that Roche’s Avastin may be reimbursed for ARMD – despite Novartis and Bayer’s challenge.
